Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loratadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 8/20 | 1.00 |
| ▸ | SLC6A15 | Q9H2J7 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loratadine SCHEMBL4596 | 1.00 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29441811 | 1.00 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL3862958 | 1.00 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL2166756 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529220 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL28800563 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529200 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529218 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL28594875 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL27891063 | 0.99 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| EP-3793518-B1 | AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES | FERTIN PHARMA AS (DK) | 2025-03-26 | — | — | EP | claimed |
| EP-4308078-B1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-03-12 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | claimed |
| EP-3801531-B1 | LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-18 | — | — | EP | claimed |
| EP-3470430-B1 | ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR | SUZHOU CONNECT BIOPHARMACEUTICALS LTD (CN) | 2024-08-28 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3793534-B1 | AN ORAL TABLET FOR DELIVERY OF ACTIVE INGREDIENTS TO THE GASTROINTESTINAL TRACT | FERTIN PHARMA AS (DK) | 2023-04-05 | — | — | EP | claimed |
| EP-3743406-B9 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2023-03-08 | — | — | EP | claimed |
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| EP-2640393-B1 | CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS | UNIV SOUTHERN CALIFORNIA (US) | 2022-10-12 | — | — | EP | claimed |
| WO-2022195044-A1 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2022-09-22 | — | — | WO | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | claimed |
| EP-3999043-A1 | PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS | SPI Pharma, INC. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3723737-B1 | POROUS SILICA PARTICLES FOR USE IN COMPRESSED PHARMACEUTICAL DOSAGE FORM | NANOLOGICA AB (SE) | 2022-05-18 | — | — | EP | claimed |
| EP-3990679-A1 | APPARATUS FOR FORMING A PLURALITY OF COATED PARTICLES, METHOD FOR FORMING A PLURALITY OF COATED PARTICLES, COATED PARTICLES | Nanexa AB (SE) | 2022-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | SMPD3, SMPD4, CMA1 | HRH1 402/4885SLC6A15 3391/4885MEN1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.